Loading...
 

Volume 33, Issue 1, March 2022



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2022;33(1):14-34
Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in Rheumatoid Arthritis Patients in Greece: Analysis of the Greek Cohort of SENSE study
Authors Information

1. Rheumatology, Clinical Immunology and Allergy, Medical School, University of Crete, Heraklion, Greece
2. OLYMPION Hospital-General Clinic of Patras, Patras, Greece
3. Outpatient Department of Rheumatology, University General Hospital of Alexandroupolis, Thrace, Greece
4. EUROMEDICA General Clinic of Thessaloniki, Thessaloniki, Greece
5. IASIO Hospital-General Clinic of Kallithea, Athens, Greece
6. Department of Rheumatology, General Hospital of Patras “Agios Andreas”, Patras, Greece
7. Private Clinic Henry Dunant Hospital Centre, Athens, Greece;
8. Medical Department, AbbVie Pharmaceuticals S.A., Neo Iraklio, Athens, Greece

P Sidiropoulos, A Bounas, N Galanopoulos, G Vosvotekas, EM Koukli, P Georgiou, N Marketos, T Antachopoulou, A Kyriakakis, M Koronaiou

Abstract

Objectives: SENSE was an international, non-interventional cross-sectional study that assessed treatment satisfaction in patients with suboptimally controlled active rheumatoid arthritis (RA) who were under treatment with any approved agent exposed to ≤ 2 biological disease-modifying antirheumatic drugs (DMARDs) at the time of enrolment. The current publication concerns the subanalysis of the results from the Greek cohort. Methods: Treatment satisfaction was assessed with Treatment Satisfaction Questionnaire for Medication (TSQM), with good treatment satisfaction defined as TSQM global ≥80. Adherence to therapy was recorded on a visual analogue scale (VAS) and treatment expectations were assessed on a 7-point numerical rating scale. Results: Of 121 patients, 82.6% were women, of mean age 64.8 years and mean time from diagnosis 8.4 years. Patients had active disease (mean DAS28-ESR 4.5) and compromised functional status (mean [SD] HAQ-DI 1.1 [0.7]) while on treatment (43.8% on biologics and 5% on steroids). The mean TSQM global was 66.9. Treatment expectations were “general improvement of arthritis” and “less joint pain” (mean score [SD], 4.9 [1.8] each), “more joint flexibility” (4.8 [1.9]), and “lasting relief of RA symptoms” (4.8 [2.1]). Oral administration was preferred by 65.3% of patients. Good self-reported adherence (≥80%) was recorded in 93.4% of the patients. Treatment switch to another DMARD was planned by treating rheumatologist for only 49.6% of the participants, despite suboptimal RA control. Conclusion: Patients with suboptimally controlled RA in Greece have low treatment satisfaction and poor self-reported outcomes, albeit high self-reported treatment adherence. Similarly to the global SENSE study results, the need for patient-centric treatment approaches in order to improve disease outcomes is emphasised.

Cite this article as: Sidiropoulos P, Bounas A, Galanopoulos N, Vosvotekas G, Koukli EM, Georgiou P, Marketos N, Antachopoulou T, Kyriakakis A, Koronaiou M. Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in Rheumatoid Arthritis Patients in Greece: Analysis of the Greek Cohort of SENSE study. Mediterr J Rheumatol 2022;33(1):14-34

Article Submitted: 15 Feb 2021; Revised Form: 16 Feb 2022; Article Accepted: 24 Feb 2022; Available Online: 31 Mar 2022

https://doi.org/10.31138/mjr.33.1.14

This work is licensed under a Creative Commons Attribution 4.0 International License.

©Sidiropoulos P, Bounas A, Galanopoulos N, Vosvotekas G, Koukli EM, Georgiou P, Marketos N, Antachopoulou T, Kyriakakis A, Koronaiou M.